For the purpose of the Examples in this Section, assume that all of the arrangements are collaborative arrangements within the scope of this Topic.
This evaluation is not intended to illustrate the appropriate revenue recognition requirements for any of the transactions described in this Example or the appropriateness of the conclusions reached on determining whether and how authoritative accounting literature applies directly or by analogy. Rather, those conclusions have been assumed as facts in this Example.
This Example illustrates the guidance in Section
808-10-45.
Pharma and Biotech agree to equally participate in the results of research and development activities for a drug candidate and in the commercialization activities if the drug candidate is approved for sale, pursuant to a joint development and marketing agreement (a 50 percent, 50 percent arrangement). Assume that Pharma and Biotech both agree to provide resources during the research and development phase, and Pharma is responsible for the commercialization activities if the drug candidate is approved for sale. As both participants are performing research and development activities, there may be periods in which Biotech must make a payment to Pharma for its proportionate share of the research and development activities and periods in which Pharma must make payments to Biotech. On a quarterly basis, Pharma and Biotech provide financial information about the research and development activities performed by both parties and the commercialization activities performed by Pharma under the joint development and marketing agreement. One participant is required to make a payment to the other participant for a proportionate share of the excess of the parties' combined operating results pursuant to their joint development and marketing agreement. In the first annual period after the product launch, Biotech and Pharma incurred research and development expenses of $10 million and $15 million, respectively. Pharma had sales to third parties of $75 million, related manufacturing expenses of $22.5 million, and marketing expenses of $20 million. As a result, Pharma owes Biotech $13.75 million, such that each participant realizes $3.75 million net profit from the arrangement (total sales of $75 million, less total expenses of $67.5 million, divided by 2). This evaluation is not intended to illustrate the appropriate revenue recognition requirements for any of the transactions described in this Example or the appropriateness of the conclusions reached on determining whether and how authoritative accounting literature applies directly or by analogy. Rather, those conclusions have been assumed as facts in this Example.
This evaluation is not intended to illustrate the appropriate revenue recognition requirements for any of the transactions described in this Example or the appropriateness of the conclusions reached on determining whether and how authoritative accounting literature applies directly or by analogy. Rather, those conclusions have been assumed as facts in this Example.
This Example illustrates the guidance in Section
808-10-45.
Studio A and Studio B agree to jointly participate in the production and distribution of a major motion picture. Studio A will manage the day-to-day production activities and will be responsible for distribution in the United States. Studio B will be responsible for distribution in Europe and Asia. Even though Studio A will be managing the production, the terms of the arrangement state that both studios will share equally in all production costs incurred. Further, Studio A will pay 50 percent of the net profits (that is, revenues less distribution costs) from the United States distribution to Studio B, and Studio B will pay 50 percent of the net profits from European and Asian distribution to Studio A. The studios are responsible for initially funding all distribution costs in their respective locations. For purposes of this example, no license to intellectual property has been conveyed to Studio B. This evaluation is not intended to illustrate the appropriate revenue recognition requirements for any of the transactions described in this Example or the appropriateness of the conclusions reached on determining whether and how authoritative accounting literature applies directly or by analogy. Rather, those conclusions have been assumed as facts in this Example.
![\"](\"/asc-img/GUID-38D3516C-08DE-4E3A-B08F-3A7B1EAF43D3-low.gif\")
Sales to third parties \" $50,000 \" \"Cost of goods sold (including $10,000 payable to Biotech for \" \" 30,000 \" profit sharing) \"Selling, general and administrative expense\" \" 10,000 \" \"Research and development expense (including $5,000 payable as a\" reimbursement of Biotech's expenses incurred) \" 5,000 \" Net profit \" $5,000 \"![\"](\"/asc-img/GUID-1BF0A0F5-F7B0-4D0D-B384-7FCEC6620F88-low.gif\")
![\"](\"/asc-img/GUID-A5BB5732-EBEF-4A81-8846-B750CC683FE9-low.gif\")
![\"](\"/asc-img/GUID-B398E2B6-9B13-45B1-B476-9AB10EEEDC2E-low.gif\")
![\"](\"/asc-img/GUID-5BAB7412-A9C3-4681-A04F-305AE6E79AFC-low.gif\")
![\"](\"/asc-img/GUID-52E42073-2E47-4C37-A51C-939F5F9F64AA-low.gif\")
![\"](\"/asc-img/GUID-9F9528EB-E479-41C4-A3C7-338A9D548936-low.gif\")